Canadian radiation oncologists' opinions regarding peer review: A national survey

Purpose: To determine Canadian radiation oncologists' (ROs) views regarding the benefits, workload implications, and legal liability of the peer review quality assurance (QA) process. Methods and materials: A 26-item anonymous survey was electronically distributed to all current practicing ROs in Canada through the Canadian Association of Radiation Oncologists membership to obtain their opinions regarding peer review. Results: The survey was completed by 145 (36%) of 404 ROs. Most (82%) reported their practice is moderately or very busy and more than two-thirds (69%) felt stressed by their workload. A peer review process is standard at 92% of respondents' institutions. The majority reported this consists of weekly meetings where ROs and other health care providers convene to review radiation treatment plans; some have tumor site-specific rounds while others have 1 meeting for all sites. Nearly all (97%) found this type of QA is beneficial for review of radical plans and 71% found it is beneficial for palliative plans. Incorporating peer review into their current work schedule for all siteswas deemed by 37% of respondents to be not or slightly difficult, while 40% found itmoderately difficult and 22% very or extremely difficult. The majority (91%) reported that creating a work code to document QA meetings would be helpful and 69% stated that extra resources such as scheduling protected time, designating other health care providers QA coordinators, and increasing overall RO manpower are needed to implement effective peer review. Over half (52%) felt documenting QA meeting minutes would increase legal liability. Conclusions: The majority of ROs who responded found that peer reviewis beneficial and participate in peer review for at least some of the tumor sites they treat. However, most stated that extra resources are required to effectively implement QA for all tumor sites in their current schedule. (C) 2015 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.